to obtain Advisors signature on any document which Advisor may be required to sign pursuant to this Section 6(c), whether because of Advisors physical or mental incapacity or for any other reason, Advisor hereby irrevocably appoints each manager of the Company (in office at the time) as Advisors attorney in fact to execute any such document on Advisors behalf.
(d) Advisor agrees to submit to the Company any proposed publication that contains any Proprietary Information, Third Party Information, Inventions or work performed by Advisor for the Company hereunder. Advisor further agrees that no such publication shall be made without the prior written consent of the Company, which consent shall not be unreasonably withheld.
(e) Advisor will not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by Advisor or any third party (including the Organization) into any Invention without the Companys prior written permission. Notwithstanding the foregoing, if Advisor incorporates into any Invention any proprietary information or other intellectual property owned by Advisor or in which Advisor has an interest and with respect to which Advisor has the right and power to grant a license to the Company, Advisor hereby grants, and to the extent any such grant cannot be made at the present, agrees to grant to the Company a non-exclusive, royalty-free, irrevocable, perpetual, transferable worldwide license, with the right to grant sublicenses through multiple tiers, under all intellectual property rights, to make, use, refrain from using, sell, offer for sale, import, modify, delete, add to, reproduce, create derivative works based upon, distribute, perform, display or otherwise exploit in any way, such proprietary information or other intellectual property, in whole or in part, by any means, not known or later developed, in all languages for the sole purposes of researching, developing, making, using selling, importing and otherwise exploiting such Invention in which such proprietary information or other intellectual property was incorporated.
(f) The terms of this Section 6 and this Agreement are subject to Advisors obligations under the Stanford Research Policies Handbook (https://doresearch.stanford.edu/policies/research-policy-handbook).
7. Noncompetition and Non-solicitation of Employees.
(a) During the term of this Agreement, Advisor will not, without the prior consent of the Company, engage in any commercial business activity in the Exclusivity Field (as defined below) that competes in any way with any business then being conducted or planned by the Company. In addition, but without limiting the generality of the foregoing, without the prior consent of the Company, Advisor covenants and agrees during the term of this Agreement not to enter into any consulting or advisory relationship in the Exclusivity Field with any third party that is non-academic and operating for-profit. The foregoing shall not prevent Advisor from engaging in Advisors work at the Organization or conducting any academic research, teaching or related non-commercial activity, including research activities sponsored by commercial entities but only to the extent that Advisors non-participation in such activities would be a violation of the policies of the academic institution by which the Advisor is employed. The term Exclusivity Field means the field of cell and gene therapy therapeutics involving the use of gene editing for the prevention and treatment of human disease where the therapeutic is produced ex vivo or where the therapeutic addresses diseases of the blood or immune system. The Exclusivity Field shall be subject to automatic expansion to include therapeutics addressing other disease areas in the event that the Board consents to (i) include additional products in the Companys development pipeline and (ii) spend material resources on these additional programs (such new therapeutics, products, and programs, the Expanded Field); provided, however, that it shall not be a breach